Double DES in bifurcations, double thrombosis risk

Original title: Late Thrombosis After Double Versus Single Drug-Eluting Stent in the Treatment of Coronary Bifurcations A Meta-analysis of Randomized and Observational Studies. Reference: Marco Zimarino et al. J Am Coll Cardiol Intv 2013. Article in press.

In the era of drug-eluting stents, (DES), several randomized and observational studies have been conducted trying to find the best strategy to deal with a bifurcation. Since most of the individual studies failed to arrive at any definitive conclusions, meta-analyzes were performed to understand the association between a double drug-eluting stent technique at a bifurcation and an increased risk of stroke but the mechanisms behind this risk were not clear.

The hypothesis of this study is that the increased risk on events using a double stent would be related to the increased rate of thrombosis. Twelve studies, (five randomized trials and seven observational), were analyzed in this meta-analysis with a total of 6,961 patients, of whom 1,868 received DES and 5,093 one single DES to treat bifurcation lesions. 

The double DES group had a higher risk of thrombosis compared with the single DES group, (RR 2.31, 95% CI, 1.33 to 4.03). This significantly increased the risk of thrombosis according primarily to observational studies, while randomized studies only showed a trend in this direction. There was also an increased risk of stroke in the double stent group, (RR 1.86, 95% CI, 1.34 to 2.35), and this significant difference was observed in all jobs. Despite the above, the all-cause mortality was similar to target vessel revascularization

Conclusion: 

Routinely, two DES implants to treat a bifurcation is associated with an increased risk of myocardial infarction compared with the technique of a single stent in the main vessel and a provisional stent in the accessory vessel. The higher incidence of infarction appears to be related to increased thrombosis. 

Comment: 

With bifurcations, as ever, the conclusion is again less is more. The second stent should always be implemented taking into account that we are doubling the chance of thrombosis and also doubling the chance of restenosis. If it is necessary, we must consider a more aggressive platelet aggregation

SOLACI.ORG

More articles by this author

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...